Jens Benn Sørensen
Clinical Associate Professor
- 2024
- Published
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial
Haakensen, V. D., Öjlert, Å. K., Thunold, S., Farooqi, S., Nowak, A. K., Chin, W. L., Grundberg, O., Szejniuk, W. M., Cedres, S., Sørensen, Jens Benn, Dalen, T. S., Lund-Iversen, M., Bjaanæs, M. & Helland, Å., 2024, In: European Journal of Cancer. 202, 6 p., 113973.Research output: Contribution to journal › Journal article › Research › peer-review
- 2023
- Published
Artificial Intelligence for Automated DWI/FLAIR Mismatch Assessment on Magnetic Resonance Imaging in Stroke: A Systematic Review
Offersen, C. M., Sørensen, Jens Benn, Sheng, K., Carlsen, Jonathan Frederik, Langkilde, Annika Reynberg, Pai, A., Truelsen, Thomas Clement & Nielsen, Michael Bachmann, 2023, In: Diagnostics. 13, 12, 15 p., 2111.Research output: Contribution to journal › Review › Research › peer-review
- Published
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
Urbanska, E. M., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2023, In: Journal of Thoracic Oncology. 18, 3, p. e28-e29Research output: Contribution to journal › Letter › Research › peer-review
- Published
New pathogenic germline variants identified in mesothelioma
Belcaid, L., Bertelsen, B., Wadt, Karin Anna Wallentin, Tuxen, I., Spanggaard, I., Højgaard, M., Sørensen, Jens Benn, Ravn, J., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Rohrberg, K. & Westmose Yde, C., 2023, In: Lung Cancer. 179, 8 p., 107172.Research output: Contribution to journal › Review › Research › peer-review
- Published
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
Urbanska, E. M., Grauslund, M., Koffeldt, P. R., Truelsen, S. L. B., Löfgren, J. O., Costa, J. C., Melchior, L. C., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2023, In: International Journal of Molecular Sciences. 24, 17, 25 p., 13077.Research output: Contribution to journal › Journal article › Research › peer-review
- 2022
- Published
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study
Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L. & 7 others, , 2022, In: Acta Oncologica. 61, 4, p. 409-416Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
Urbanska, E. M., Sørensen, Jens Benn, Melchior, L. C., Costa, J. C. & Santoni Rugiu, Eric, 2022, In: JCO Precision Oncology. 6, 6, 6 p., e2200040.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study
Sørensen, Jens Benn, Horvat, P., Rosenlund, M., Kejs, A. M., Patel, D., Juarez-Garcia, A., Lacoin, L., Daumont, M. J., Penrod, J. R., O'donnell, J. C., Brustugun, O. T. & Ekman, S., 2022, In: Future Oncology. 18, 2, p. 205-214 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- 2021
- Published
Correlation of MET-receptor overexpression with MET gene amplification and patient outcome in malignant mesothelioma
Santoni Rugiu, Eric, Lü, M. J. S., Jakobsen, J. N., Melchior, L. C., Ravn, J. & Sørensen, Jens Benn, 2021, In: International Journal of Molecular Sciences. 22, 23, 20 p., 12868.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery
Urbanska, E. M., Santoni Rugiu, Eric, Melchior, L. C., Carlsen, Jonathan Frederik & Sørensen, Jens Benn, 2021, In: Clinical Lung Cancer. 22, 4, p. e528-e532 5 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 34406177
Most downloads
-
162
downloads
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
99
downloads
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
72
downloads
Very Early Response Evaluation by PET/MR in Patients with Lung Cancer: Timing and Feasibility
Research output: Contribution to journal › Journal article › Research › peer-review
Published